Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 6, Pages 2574-2584Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm2016057
Keywords
-
Categories
Ask authors/readers for more resources
The bradykinin (BK) B1 receptor is an attractive target for the treatment of chronic pain and inflammation. Starting from a dual B1 and B2 antagonist, novel antagonists were designed that display low-nanomolar affinity for human B1 receptor and selectivity over B2. Initially, potent imidazoline derivatives were studied, but these compounds suffered from low bioavailability. This issue could be overcome by the use of less basic amino derivatives leading to orally active compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available